The utility of surrogate markers in predicting HLA alleles associated with adverse drug reactions in Vietnamese

Dinh Van Nguyen,1,2,3 Janet Anderson,1 Christopher Vidal,1 Richard Fulton,1 Jamma Li,1,2,4 Suran L Fernando1,2,4

Abstract

**Background:** Screening for HLA-A*31:01/HLA-B*15:02, HLA-B*57:01 and HLA-B*58:01 is recommended in selected populations for prevention of carbamazepine, abacavir, and allopurinol-induced severe cutaneous adverse reactions (SCARs). Compared to conventional methods for detection of HLA alleles, PCR using a tag single nucleotide polymorphism (SNP) can be cost-effective, particularly where the surrogate marker SNP is in absolute linkage disequilibrium with the relevant HLA allele.

**Objective:** To determine guidelines for prevention of SCARs though predictive screening for the Australian Vietnamese population, the prevalence of four HLA alleles (HLA-A*31:01, HLA-B*15:02, HLA-B*57:01 and HLA-B*58:01) was examined. The utility of surrogate markers, rs2395029 and rs9263726, was investigated to predict for the presence of HLA-B*57:01 and HLA-B*58:01, respectively.

**Methods:** Genotyping for specific HLA alleles was performed in 152 healthy Vietnamese living in Sydney using validated and established PCR-based methods. SNP genotyping was conducted using restriction-fragment-length-polymorphism analysis.

**Results:** rs2395029 and rs9263726 strongly correlated with HLA-B*57:01 (κ = 1, p < 0.001) and HLA-B*58:01 (κ = 0.9, p < 0.001) with 100% sensitivity and 100% negative predictive value for predicting the HLA-B*57:01 and HLA-B*58:01 carriers, respectively. A high prevalence of carriers of HLA-A*31:01 (3.29%), HLA-B*15:02 (14.47%), HLA-B*57:01 (6.58%) and HLA-B*58:01 (9.21%) was revealed.

**Conclusions:** Screening is recommended for these alleles in Australian Vietnamese prior to introducing relevant therapies. SNPs, rs2395029 and rs9263726, can be successfully used as surrogate markers for HLA-B*57:01 and HLA-B*58:01 in this population.

**Key words:** HLA, polymorphisms, abacavir, allopurinol, carbamazepine, Toxic Epidermal Necrolysis, Stevens-Johnson syndrome, Drug Rash with Eosinophilia and Systemic Symptoms, Vietnamese

From:
1 ImmunoRheumatology Laboratory, New South Wales Health Pathology-North, Royal North Shore Hospital, Sydney, Australia
2 Sydney Medical School-Northern, The University of Sydney, Sydney, Australia
3 Division of Allergy and Clinical Immunology, Vinmec International Hospital Times City, Hanoi, Vietnam
4 Department of Clinical Immunology and Allergy, Royal North Shore Hospital, Sydney, Australia

* Corresponding author:
Suran L Fernando
ImmunoRheumatology Laboratory, NSW Health Pathology-North, Royal North Shore Hospital, Reserve Road, St Leonards. NSW 2065 Australia
E-mail: Suran.Fernando@health.nsw.gov.au

Introduction

The associations between immunologically mediated adverse drug reactions and certain Human Leukocyte Antigens (HLA) alleles have been well documented with an increasing body of information detailing genetic risk factors associated with these reactions. Commonly described associations include the HLA-B*15:02 and HLA-A*31:01 alleles with carbamazepine (CBZ)-induced severe cutaneous adverse drug reactions (SCARs), HLA-B*58:01 with allopurinol-induced SCARs and HLA-B*57:01 with abacavir (ABC)-induced hypersensitivity reactions. In particular, a strong association between the
The benefit of HLA screening relies on the prevalence of these alleles. The prevalence of four specific HLA alleles (HLA-A*31:01, HLA-B*15:02, HLA-B*57:01 and HLA-B*58:01) in Vietnamese in Australia has been utilized to predict HLA alleles associated with adverse drug reactions, based on linkage disequilibrium (LD) and are useful as surrogate markers in specified populations. In 2006, de Bakker et al. reported complete LD between rs3909184 and HLA-B*15:02 in 45 Han Chinese individuals and between rs1061235 and HLA-A*31:01 in 182 Caucasian, 44 Japanese and the 45 Han Chinese individuals, respectively. Additionally, complete LD between rs2395029 and HLA-B*57:01 was found in the Caucasian cohort. Complete LD has also been reported for rs9263726, a SNP within the psoriasis susceptibility 1 gene, with HLA-B*57:01 in a Japanese cohort with a strong correlation also seen in a study of Eastern Chinese patients with SCARs. The accuracy, however, of these SNPs to predict particular HLA alleles varies across multiple populations. Notably, LD of rs9263726 with HLA-B*57:01 has been confirmed at least one biological parent to be of Vietnamese origin. The study was approved by Northern Sydney Health District HREC (HREC/15/HAWKE/86). Buccal swab samples were collected after obtaining informed consent.

Methods

Sample population

This study included 152, randomly recruited, healthy unrelated individuals of Vietnamese ancestry (82 males and 70 females, median age 30 years, range 18-83). Participants were currently living in Sydney, New South Wales. Further, there is no data on the prevalence of HLA alleles associated with adverse drug reactions in this group. It would therefore be informative to assess the prevalence of these HLA alleles to assist with the formulation of predictive screening guidelines for the prevention of SCARs in Vietnamese in Australia.

This study was therefore initiated to determine the prevalence of four specific HLA alleles (HLA-A*31:01, HLA-B*15:02, HLA-B*57:01 and HLA-B*58:01) in Vietnamese in Australia and to evaluate the utility of the surrogate markers rs2395029 and rs9263726, to predict the presence of HLA-B*57:01 and HLA-B*58:01 alleles respectively, in this population group.

DNA extraction

Genomic DNA was extracted from buccal swabs (CEPTM Swab, Fitzco*, Spring Park, MN, USA) as per manufacturer’s instructions (AccuPrep Genomic DNA Extraction kit, Bioneer Corp, Daejeon, South Korea). The quality of genomic DNA was analysed by spectrophotometry using the Implen Nano-Photometer® yielding an average DNA concentration of 25 ng/µl and an average of A260/280 ratio of 1.7.
**HLA genotyping**

HLA-A*31:01/HLA-B*15:02 alleles were detected using a multiplex real-time PCR assay with TaqMan® probes. Detection of HLA-B*58:01/57:01 alleles was performed using a multiplex real-time PCR assay with TaqMan® probes followed by real-time PCR with SYBR® Green for confirmation of HLA-B*58:01 and a nested PCR protocol for typing of HLA-B*57:01.

**SNP genotyping**

Genotyping for SNPs (rs2395029 T>G and rs9263726 G>A) was performed using a PCR restriction fragment length polymorphism (RFLP) technique. Oligonucleotide primers were designed using IDT’s PrimerQuest Tool incorporating Primer3 software (version 2.2.3) (Integrated DNA Technologies, Skokie, IL, USA) and synthesized by Bioneer (Bioneer Corp, Daejeon, South Korea). A 260 bp amplicon harbouring SNP rs9263726 (Forward primer: 5’-AAG CTC CAT CCA CCC CTG GT-3’ and Reverse primer: 5’-ACA CAT TGG GTG GGG GAC AT-3’) and a 576 bp amplicon harbouring SNP rs2395029 (Forward primer: 5’-GTC TGG GCT CTT GGA AAT CA-3’ and Reverse primer: 5’-GCT TCT ATA GGC ACA GCT CAA-3’) were amplified, respectively. PCR was performed in a total volume of 25 µl including 20 µl of reaction mixture [12.5 µl GoTaq® Green Master Mix (Promega Corp, Madison, WI, USA), 0.5 µl primers (100 pmol/ µl), PCR grade water to final volume] and 5 µl of input genomic DNA. PCR conditions: Hot-start: 94°C for 10 min, Denature: 94°C for 30 sec, Annealing: 65°C for 30 sec, Extension: 72°C for 30 sec, Final extension: 72°C for 5 min. Total cycles: 35. For SNP rs9263726, a 25 µl reaction volume consisting of PCR products and 2.5 units of restriction enzyme FokI (New England Biolabs, Ipswich, MA, USA) was incubated at 37°C for 60 min, followed by enzyme inactivation at 65°C for 20 min. The restriction enzyme cleaves the PCR product in the presence of the A allele, yielding fragments of 141 bp and 119 bp (Figure 1). For SNP

---

**Figure 1. Demonstration of SNP rs9263726 genotyping.**

(A) PCR product fragments on 1.2% agarose gel (FlashGel® Cassette, Lonza, Allendale, NJ, USA) after FokI digestion. Track 1 is the ladder. Track 9 is a heterozygous (GA) sample. (B) shows the sequence of the SNP rs9263726 heterozygous (GA-R). (C) shows the sequence of the SNP rs9263726 wild type (GG).
Figure 2. Demonstration of SNP rs2395029 genotyping.

(A) PCR product fragments on 1.2% agarose gel (FlashGel® Cassette, Lonza, Allendale, NJ, USA) electrophoresis after XcmI digestion. Track 7 is the ladder. Tracks 1 and 2 are heterozygous (GT) samples. (B) shows the sequence of the heterozygous (GT-K) SNP rs2395029. (C) shows the sequence of the wild type (TT) of SNP rs2395029.

rs2395029, a 25 µl reaction volume consisting of the PCR products and 2.5 units of restriction enzyme XcmI (New England Biolabs, Ipswich, MA, USA) was incubated at 37°C for 60 min, followed by enzyme inactivation at 65°C for 20 min. The restriction enzyme cleaves the PCR product in the presence of the T allele, yielding fragments of 328 bp and 248 bp (Figure 2).

Fragments of digested PCR products were visualised on 1.2% agarose gel (FlashGel® Cassette, Lonza, Allendale, NJ, USA). Selected samples were confirmed by direct DNA sequencing using BigDye terminators v3.1 (Applied Biosystems, Waltham, WA, USA) (Figure 1A, B, C and Figure 2A, B, C).

Data analysis

Data was analysed using IBM SPSS Statistics software, version 22.0 (IBM SPSS, Armonk, NY, USA) including determination of the prevalence of each HLA allele (HLA-A*31:01, HLA-B*15:02, HLA-B*57:01 and HLA-B*58:01) and analysis of agreement between the surrogate marker SNPs (rs2395029 and rs9263726) and the relevant tagged HLA allele. The ability of each SNP (to potentially predict HLA-B*57:01 and HLA-B*58:01, was additionally assessed by determination of sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). A web-based tool29 was used to test for Hardy-Weinberg Equilibrium (HWE) of each SNP. A P value of < 0.05 was considered as statistically significant.

Results

Prevalence of carriers for HLA-A*31:01, HLA-B*15:02, HLA-B*57:01 and HLA-B*58:01 in the Vietnamese population in Australia

In this study, we successfully detected HLA-A*31:01, HLA-B*15:02, HLA-B*57:01 and HLA-B*58:01 in genomic DNA extracted from buccal swabs collected from healthy unrelated individuals of Vietnamese ancestry, using well validated real-time PCR methods. Results revealed the overall prevalence of carriers for HLA-A*31:01 (3.29%), HLA-B*15:02 (14.47%), HLA-B*57:01 (6.58%) and HLA-B*58:01 (9.21%) in this Vietnamese Australian cohort.
Comparison of these results with figures from studies in Vietnamese populations from other geographical regions, shows that the prevalence of HLA-A*31:01, HLA-B*15:02, HLA-B*57:01 and HLA-B*58:01 carriers in our study group is similar to that reported in Vietnamese populations in Vietnam and the United States (Table 1).

In comparison to non-Vietnamese populations, the HLA-B*15:02 and HLA-B*58:01 alleles in particular were found with higher frequency in our cohort than in a Caucasian population (Table 1). Additionally, the prevalence of HLA-B*57:01 carriers was higher in the study population than in a Chinese population. The high prevalence of these alleles in our study cohort indicates that individuals of Vietnamese ancestry may be at high risk for carbamazepine and allopurinol-induced SCARs and for abacavir-induced hypersensitivity reactions.

**Correlation of rs2395029 T>G and HLA-B*57:01**

Of 152 samples, 10 which were identified as heterozygous carriers of the G allele of SNP rs2395029, were also positive for HLA-B*57:01. The distribution of this SNP was in perfect HWE (T = 0.97, G = 0.03, $\chi^2 = 0.18$, p > 0.05). There was a perfect agreement between HLA-B*57:01 and the SNP rs2395029 ($\kappa = 1.0$, p < 0.001). The result is consistent with the findings across ethnic populations\(^{12,30}\) over the world, and indicates that SNP rs2395029 is an effective surrogate marker to detect HLA-B*57:01 in individuals of Vietnamese ancestry, with calculated sensitivity, specificity, NPV and PPV all of 100% in our cohort group (Table 2).

**Correlation of rs9263726 G>A and HLA-B*58:01**

Genotyping of SNP rs9263726, revealed 17 heterozygous carriers of the A allele, of which 15 samples were positive for HLA-B*58:01. There was strong agreement between HLA-B*58:01 and the SNP rs9263726 ($\kappa = 0.9$, p < 0.001). The distribution of this SNP was in perfect HWE (G = 0.94, A = 0.06, $\chi^2 = 0.53$, p > 0.05). This finding indicates that SNP rs9263726 genotyping is an appropriate method for screening HLA-B*58:01 carriers within the Australian Vietnamese population with high sensitivity, specificity, NPV and PPV again indicated (Table 3).

On further investigation, 2 of the 3 unmatched samples for HLA-B*58:01 and SNP rs9263726 (one DNA sample was of insufficient quantity) were genotyped using Luminex SSO/ SBT/SSP (Australian Red Cross Blood Service). Genotypes were revealed to be HLA-B*40:01/HLA-B*40:06 and HLA-B*07:05-06/HLA-B*18:01.
Discussion

With a total number of 294,798, the Vietnamese population is the ninth largest racial group represented in Australia. In this study, we determined the prevalence of HLA alleles associated with adverse drug reactions in the Vietnamese population in Australia. The high prevalence of carriers for these alleles within the Vietnamese Australian population provides strong evidence for the utility of pharmacogenetic screening to aid in the prevention of CBZ, allopurinol, and ABC-induced severe adverse reactions in this group. Furthermore, the presence of both HLA-B*15:02 (14.47%) and HLA-A*31:01 (3.29%) carriers in our sample cohort, supports the utility of a multiplex assay as a cost effective screening tool for both alleles associated with CBZ-induced SCARs. This assay may additionally prove beneficial in other racial groups living in Australia, such as the Han Chinese, in which racial admixture results in maintenance of a high prevalence of HLA-B*15:02 and a rise in the frequency of HLA-A*31:01.

A number of recent studies have demonstrated that the cost-effectiveness of HLA screening relies on three crucial elements: the cost of treatment, the cost of the screening test and the prevalence of the culprit HLA allele in association with its PPV. Dong et al. indicated that HLA screening is likely to be most cost-effective in populations where HLA-B*15:02 prevalence is greater than 5%, while screening for HLA-A*31:01 is indicated to be cost-effective in populations with an allelic prevalence greater than 2.5%. The current study reveals prevalence figures greater than these values in each case and thus supports cost effective screening for these markers in our study population. With respect to the HLA-B*57:01 allele a high PPV of 47.9% has been reported for detection of hypersensitivity to abacavir. While the allelic prevalence is highest in white Caucasians (4.8%) as compared to African Americans (2.3%), Han Chinese and Africans (< 1%) the increasing rates of ethnic admixture and the increasing availability of predictive HLA-B*57:01 screening assays, has resulted in recommendation of testing for all individuals. Again, screening is more likely to be cost effective in populations where HLA-B*57:01 prevalence is high. The current study showed a prevalence of 6.58% for HLA-B*57:01 in Vietnamese in Australia and therefore cost effective screening could be recommended for this allele prior to commencing abacavir therapy.

The association of rs9263726 and HLA-B*58:01 demonstrated in this study is consistent with previous findings in a case-control study of allopurinol-induced SCARs conducted in Vietnam. This confirms the utility of the rs9263726 SNP as a surrogate marker for prediction of susceptibility to allopurinol-induced SCARs in individuals of Vietnamese ethnicity. The high (100%) NPV of the test, relative to the presence of the HLA-B*5801 allele, minimizes the risk of exposing a potentially susceptible patient to a severe adverse drug reaction due to treatment with allopurinol. The presence of three HLA-B*58:01 negative carriers possessing the A allele of rs9263726 and contributing to a slightly reduced PPV (82.4%) agrees with data suggesting that rs9263726 is not in absolute LD with HLA-B*5801 across varying populations. Such false positive results however, do not increase the risk of adverse reactions, though ideally confirmatory testing for HLA-B*58:01 should be performed in positive cases to avoid any unnecessary denial of allopurinol treatment.

The strong association of rs2395029 and HLA-B*57:01 in this study indicates that this SNP may successfully be used as a marker to predict the presence or absence of HLA-B*57:01 carriage in Vietnamese individuals. Compared to other methods currently in use for HLA-B*57:01 screening, SNP genotyping with a surrogate marker is a reliable, simple, accessible and affordable method. There are approximately 250,000 people living with HIV infection in Vietnam, many in rural and mountainous regions of the country. Antiretroviral coverage reached 50% by 2017. The U.S Department of Health and Human Services recommends abacavir based antiretroviral therapy as one of the first line options for treatment naïve patients. The availability of a cost effective screening method in Vietnam for the detection of HLA-B*57:01 would not only prevent abacavir-induced hypersensitivity reactions but also allow for expansion of the availability of this antiretroviral drug. The ability, therefore, to perform onsite predictive testing for rs2395029 would be particularly attractive for remote settings in Vietnam.

In this study, successful genotyping for HLA using real-time PCR assay and SNPs using basic PCR-RFLP indicates that buccal swabs provide a sufficient DNA quality for implementing pharmacogenetic screening. Compared to blood collection, a buccal swab is non-invasive, more portable and more suitable for special populations such as children and elderly patients. Buccal swabs are also suitable for dealing with infectious samples, including HIV-infected samples.

In conclusion, the strong correlations between rs2395029 and HLA-B*57:01 and between rs9263726 and HLA-B*58:01, observed in this study, confirm the utility of these surrogate markers in the identification of HLA-B*57:01 and HLA-B*58:01 carriers. The availability of these simple and relatively less expensive methodologies may facilitate implementation of pharmacogenetic screening in Vietnamese populations in varying geographical locations and particularly in Vietnam where there is a lack of resources for HLA genotyping. The high prevalence of carriers for HLA-A*31:01, HLA-B*15:02, HLA-B*57:01 and HLA-B*58:01 in individuals of Vietnamese ancestry in Australia is consistent with figures noted for Vietnamese populations residing in other areas of the world and supports the implementation of HLA screening for the prevention of CBZ, allopurinol and abacavir hypersensitivity in this population group.

Acknowledgements

We would like to acknowledge all the Vietnamese participants who generously donated samples for this study. We also thank Dr Ngo Quang, a primary care physician at Marrickville Medical Centre and Van Son Tran, a PhD candidate at University of Technology, Sydney for their assistance in the collection of samples. We thank Ms Anne Proos and the staff in the Department of Molecular Genetics, NSW Health Pathology-North, Royal North Shore Hospital for the use of their facilities. We are also grateful to Australia Awards Scholarship for supporting Dr Dinh Van Nguyen and the NSW Health Pathology-North Immunology Trust Fund for funding this study.
Conflicts of interest
None

Funding
This work was supported by the NSW Health Pathology-North Trust Fund. Dr Dinh Van Nguyen was supported by an Australia Awards Scholarship.

References